Profil
Michael Boretti worked as Vice President of Corporate Development at AVEO Pharmaceuticals, Inc. He then worked as Vice President of Business Development at Epizyme, Inc. from 2016 to 2019.
Boretti received his undergraduate degree from the University of Virginia and his doctorate from the University of Pennsylvania.
Anciens postes connus de Michael Boretti
Sociétés | Poste | Fin |
---|---|---|
EPIZYME, INC. | Corporate Officer/Principal | 01/04/2019 |
AVEO PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formation de Michael Boretti
University of Virginia | Undergraduate Degree |
University of Pennsylvania | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |